National Health (Listed drugs on F1 or F2) Amendment Determination 2020 (No. 3) (PB 26 of 2020) (Cth)

PB 26 of 2020

National Health (Listed drugs on F1 or F2) Amendment Determination 2020 (No. 3)

National Health Act 1953

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated      30 March 2020

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

Part 1         Preliminary

1. Name of Determination

(1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2020 (No. 3).

(2)   This Determination may also be cited as PB 26 of 2020.

1. Commencement

This Determination commences on 1 April 2020.

1. Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).

Schedule 1             Amendments

(Section 3)

[1]     Schedule 1, after item dealing with Bevacizumab

Insert

Binimetinib

[2]     Schedule 1, after item dealing with Clostridium Botulinum Type A Toxin-haemagglutinin Complex

Omit

Coal tar

[3]     Schedule 1, after item dealing with Emtricitabine with tenofovir alafenamide

Insert

Encorafenib

[4]     Schedule 1, after item dealing with Mifepristone and misoprostol

Omit

Milk powder lactose intolerance formula

[5]     Schedule 1, after item dealing with Mepolizumab

Omit

Mercaptopurine

[6]     Schedule 2, after item dealing with Memantine

Insert

Mercaptopurine

[7]     Schedule 2, after item dealing with Olmesartan with amlodipine

Insert

Olmesartan with amlodipine and hydrochlorothiazide

[8]     Schedule 2, after item dealing with Timolol

Omit

Tinidazole